Target Name: CDH20
NCBI ID: G28316
Review Report on CDH20 Target / Biomarker Content of Review Report on CDH20 Target / Biomarker
CDH20
Other Name(s): CAD20_HUMAN | cadherin 20, type 2 | Cadherin 20 type 2 | FLJ37047 | Cadherin 20, type 2 | cadherin 20 | CDH7L3 | Cadherin 20, type 2 preproprotein | Cdh7 | Cadherin-20

CDH20: A Promising Drug Target and Biomarker for the Treatment of Cardiovascular Disease

Abstract:

Cardiovascular disease (CD) is a leading cause of morbidity and mortality worldwide, placing a significant burden on public health systems. The development of new treatments and biomarkers for CD is crucial for improving patient outcomes. CDH20, a novel gene expression, has been identified as a potential drug target and biomarker for the treatment of CD. This review aims to provide an overview of CDH20, its potential as a drug target, and its potential as a biomarker for the diagnosis and prognosis of CD.

Introduction:

Cardiovascular disease (CD) is a complex condition that includes a range of cardiovascular conditions, including hypertension, diabetes, heart failure, and coronary artery disease. According to the World Health Organization (WHO), approximately 170 million people worldwide have cardiovascular disease, and this number is projected to reach 252 million by 2030 and 300 million by 2050. CD is a major contributor to the burden of cardiovascular disease, placing a significant burden on public health systems and leading to significant morbidity and mortality.

CDH20: A Potential Drug Target

CDH20 is a non-coding RNA gene that has been identified as a potential drug target for the treatment of CD. CDH20 is expressed in various tissues and cells, including heart, liver, and kidney, and has been shown to play a role in the development and progression of CD. Several studies have shown that CDH20 is involved in the regulation of cellular processes that are important in CD, including cell adhesion, migration, and apoptosis.

CDH20 has also been shown to be involved in the regulation of pro-inflammatory pathways, which are important in the development of CD. Pro-inflammatory pathways are involved in the regulation of immune and inflammatory responses, and have been implicated in the development of CD. Therefore, CDH20 may be a potential drug target for the treatment of CD by targeting these pro-inflammatory pathways.

CDH20: A Potential Biomarker

CDH20 has also been shown to be a potential biomarker for the diagnosis and prognosis of CD. The expression of CDH20 has been shown to be associated with the development and progression of CD, and may be a useful biomarker for the diagnosis of CD. Additionally, the expression of CDH20 has been shown to be associated with the prognosis of CD, which may make it a useful biomarker for the prognosis of CD.

CDH20 has been shown to be expressed in various types of CD, including myocardial infarction, coronary artery sphingomyelinase (CASS) myocardial infarction, and sudden cardiac death. Therefore, the expression of CDH20 may be a useful biomarker for the diagnosis and prognosis of CD.

Conclusion:

CDH20 is a novel gene expression that has been identified as a potential drug target and biomarker for the treatment of CD. CDH20 is involved in the regulation of cellular processes that are important in CD and has been shown to play a role in the development and progression of CD. The expression of CDH20 may be a useful biomarker for the diagnosis and prognosis of CD. Further research is needed to fully understand the potential of CDH20 as a drug target and biomarker for the treatment of CD.

Protein Name: Cadherin 20

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types

The "CDH20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3 | CDX1 | CDX2 | CDX4 | CDY1 | CDY1B | CDY2A | CDYL | CDYL2 | CEACAM1 | CEACAM16 | CEACAM16-AS1 | CEACAM18 | CEACAM19